Business Context and Reporting Period
Company: Silo Pharma, Inc. (formerly Uppercut Brands, Inc., Point Capital, Inc., and Gold Swap, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: October 20, 2020
Reporting Period: The filing provides a description of business operations and risk factors as of the report date, referencing financial data through December 31, 2019.
The Company is pivoting from a streetwear apparel business (NFID brand) to a biotechnology focus on rare disease therapeutics, specifically exploring psychedelic drugs like psilocybin for mental health and neurological disorders. The Company operates through a wholly-owned Florida subsidiary, Silo Pharma, Inc.
Key Financial Metrics
The filing references historical financial data from the fiscal year ended December 31, 2019, but does not provide current period (2020) financial statements.
| Metric | Value (FY 2019) | Value (FY 2018) |
|---|---|---|
| Net Loss | $1,013,294 | $969,463 |
| Cash Used in Operations | $794,324 | N/A |
| Accumulated Deficit | $2,655,804 | N/A |
| Stockholders' Deficit | $22,892 | N/A |
| Revenues | Minimal (No specific value provided) | N/A |
Liquidity and Debt: The filing states there is substantial doubt about the Company's ability to continue as a going concern. The Company has no history of profitability and has not achieved positive monthly cash flow. It requires additional financing to fund operations and cover public reporting costs.
Material Changes and Recent Developments
- Strategic Pivot: Management is actively expanding into rare disease therapeutics, specifically targeting depression, PTSD, Parkinson's, and multiple sclerosis using psilocybin and central nervous system-homing peptides.
- Corporate Name Change: The Company changed its name from "Uppercut Brands, Inc." to "Silo Pharma, Inc." effective September 24, 2020.
- Board Appointment: Dr. Kevin Muñoz was appointed as an independent director effective October 1, 2020, serving on the Audit and Compensation Committees.
- Strategic Agreement: On July 15, 2020, the Company entered into a commercial evaluation license and option agreement with the University of Maryland, Baltimore (UMD) regarding CNS-homing peptides. An initial license fee of $10,000 was due within 30 days.
- Intellectual Property: The Company has filed three patent applications related to the delivery of compounds (including psilocybin) for treating arthritis and CNS diseases.
Guidance, Outlook, Risks, and Contingencies
Outlook and Guidance: The Company provides no specific financial guidance. Management states that the ability to continue as a going concern depends on generating sufficient revenues, limiting expenses, and obtaining necessary financing. The Company plans to actively pursue acquisitions and development of IP for rare diseases.
Material Risks:
- Going Concern: Substantial doubt exists regarding the Company's ability to continue operations due to accumulated deficits and lack of profitability.
- Regulatory Hurdles: Psilocybin is a Schedule I controlled substance. Commercialization requires FDA approval and potential rescheduling by the DEA, which is uncertain and time-consuming.
- Internal Controls: The Company identified a material weakness in internal control over financial reporting for the year ended December 31, 2019, citing a lack of segregation of duties and inadequate system controls.
- Financing: The Company has no arrangements in place to raise all needed capital and may be forced to curtail operations if funding is not secured.
- Intellectual Property: Risks include the failure to obtain patents, challenges to existing IP, and potential infringement claims.
Investor Verification Checklist
- Verify the Company's current cash position and runway, given the "substantial doubt" regarding going concern status.
- Confirm the status of the $10,000 initial license fee payment to the University of Maryland, Baltimore.
- Review the specific terms of the UMD option agreement to understand future milestone obligations.
- Assess the progress of the three filed patent applications and the likelihood of issuance.
- Monitor the Company's ability to remediate the identified material weakness in internal controls.
- Track any updates on the rescheduling of psilocybin by the DEA or FDA approval pathways for the proposed therapies.